Literature DB >> 1554923

Prospective trial on captopril-related cough.

J Lefebvre1, L Poirier, Y Lacourcière.   

Abstract

OBJECTIVE: Quantify and characterize cough as an adverse reaction secondary to captopril.
DESIGN: Cohort analytic study: six-month prospective trial including two-week, placebo, run-in period; five-month, single-blind, active treatment; and two-week, dechallenge period.
SETTING: Outpatient clinic. PATIENTS: 199 previously treated or newly diagnosed untreated patients with mild to moderate hypertension.
INTERVENTIONS: Captopril 50 mg/d during five months. OUTCOME MEASURES: Self-questionnaires, interviews, dechallenge, and rechallenge periods. Naranjo's algorithm. RESULTS AND
CONCLUSIONS: (1) Cumulative incidence of captopril-induced cough over a five-month period was 7.1 percent (95 percent C.I., 6.8-7.4 percent). Incidence of drug withdrawal secondary to severe cough was 1.0 percent; this figure is somewhat similar to first reports about the reaction. (2) Cough was a generally mild to moderate symptom, present day and night in 71.4 percent of patients and resistant to antitussive agents. Cough was not statistically related to sex, age, or smoking habit; however, the female gender and the development of a common cold may be predisposing factors.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1554923     DOI: 10.1177/106002809202600202

Source DB:  PubMed          Journal:  Ann Pharmacother        ISSN: 1060-0280            Impact factor:   3.154


  3 in total

1.  Cough due to ACE inhibitors: a case-control study using automated general practice data.

Authors:  L E Visser; A E Vlug; J van der Lei; B H Stricker
Journal:  Eur J Clin Pharmacol       Date:  1996       Impact factor: 2.953

Review 2.  Drug-induced respiratory disorders: incidence, prevention and management.

Authors:  L Ben-Noun
Journal:  Drug Saf       Date:  2000-08       Impact factor: 5.606

3.  Reproducibility of angiotensin converting enzyme inhibitor induced cough: a double-blind randomised study.

Authors:  V Charlon; S Dollow; J Fidel; C Hoglund; T Honkanen; I Kobrin; J McEwan; G McInnes; J R Viskoper; K S Woo
Journal:  Br J Clin Pharmacol       Date:  1995-02       Impact factor: 4.335

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.